Newsletter | May 21, 2024

05.21.24 -- Overcoming Bioprocessing Challenges Through A Strategic Tech Transfer Framework

Considerations For Successful Upstream Manufacturing Process Scale-Up

Bispecific antibodies (bsAbs) are revolutionizing medicine by targeting two disease mechanisms simultaneously. However, the intricate structure of bsAbs presents a significant roadblock in their development and manufacturing. Learn how an innovative platform offers excellent pairing and significantly enhances productivity and quality.


Tech Transfer Best Practices: Facility Fit And Process Gap Assessments

An experienced contract manufacturer can help drug developers to better utilize valuable internal resources, leverage a deep pool of industry experience, and mitigate risk across development cycles — staying competitive in a rapidly evolving market. However, finding the right combination of services, culture, expertise, and capacity is critical.


Bioprocessing Optimization: How MSAT Drives Efficient Tech Transfer

Complex biomanufacturing and shifting regulations necessitate effective tech transfer for the timely delivery of treatments. A CDMO’s manufacturing science and technology (MSAT) integrates foundational technical and engineering expertise with regulatory and business considerations to optimize bioprocessing for large-scale manufacturing.




Samsung Biologics, Your End-To-End CDMO Service Provider

Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish for biologics. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.


•  Download Samsung Biologics Corporate Brochure

•  Download Samsung Biologics ADC Brochure

•  Download Samsung Biologics CDO Brochure


Request Information